CN1140066A - Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation - Google Patents
Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation Download PDFInfo
- Publication number
- CN1140066A CN1140066A CN 95107235 CN95107235A CN1140066A CN 1140066 A CN1140066 A CN 1140066A CN 95107235 CN95107235 CN 95107235 CN 95107235 A CN95107235 A CN 95107235A CN 1140066 A CN1140066 A CN 1140066A
- Authority
- CN
- China
- Prior art keywords
- radix
- fruit
- hirudo
- hippocampus
- succinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An oral medicine for treating the gangrene of finger or toe, as well as the obstruction of Qi in the chest and apoplexy caused by stuck circulation of blood and Qi is prepared from 13 Chinese-medicinal materials such as Chinese azale fruit, leech, notoginseng, Chuan-xiong rhizome, frankincense, myrrh, etc. through water extraction, baking, crushing and mixing.
Description
The present invention relates to a kind of Chinese medicine preparation, particularly a kind of preparation for the treatment of thromboangiitis obliterans and cardiovascular and cerebrovascular disease.
Thromboangiitis obliterans also claims necrosis disease, claims " gangrene of finger or toe " again, is one of common peripheral angiopathy.Morbidity is a cardinal symptom with affected part pain and extremity gangrene, is mainly between twenty and fifty man, and the sickness rate of cold humid area is higher, and the morbidity later stage often disables and disability.The cause of disease is not clear and definite fully as yet, it is generally acknowledged that the generation of primary disease is relevant with smoking cold, humidity, malnutrition, gonadal hormone and Nervous and Mental Factors etc., in recent years, also has the primary disease of thinking to belong to autoimmune disease.Modern medicine adopts operative treatment more, and is not only painful big, and the long-term effect of operative treatment is dissatisfied, and specific medicament targetedly not also so far on the market.
The objective of the invention is to lead to is the rule of treatment, with blood circulation promoting and blood stasis dispelling, and promoting blood circulation, warming YANG and invigorating QI, a kind of " Maitongling " oral preparation for promoting blood circulation for the treatment of thromboangiitis obliterans is formulated out in the invigorating the liver and kidney legislation.
The present invention realizes in such a way: according to the theory of Chinese medicine, necrosis disease is that deficiency of vital QI can not be resisted due to the exopathogen simulataneous insufficiency and excessive, deficiency in origin and excess in superficiality owing to deficiency of the liver and kindey.Blood flow not general rule is the common ground of Chinese and western medicine understanding, and the differentiation of symptoms and signs for classification of syndrome cold-damp is held concurrently empty in the majority, and the heresy that pyretic toxicity is more common in necrosis mid-term or is experienced pyretic toxicity forms, therefore, in treatment with logical be the rule of treatment, with blood circulation promoting and blood stasis dispelling, promoting blood circulation, warming YANG and invigorating QI, invigorating the liver and kidney legislation.On the prescription of preparation, be monarch drug with the fruit of Chinese Azalea, after it was concocted, this medical instrument had the effect of promoting blood circulation to remove blood stasis, removing damp and stopping pain, with Radix Notoginseng, Hirudo is ministerial drug, and Hirudo has removing blood stasis, and dissipating blood stasis stimulates the menstrual flow, the Radix Notoginseng dissipating blood stasis that then stops blooding, subduing swelling and relieving pain, with Hirudo with 5 principal drug assistance promoting blood circulation and breaking stagnations, pain relieving; Radix Ginseng, Cornu Cervi Pantotrichum, Hippocampus also are ministerial drug, Radix Ginseng strongly invigorating primordial QI wherein, and invigorating the spleen and replenishing QI, Cornu Cervi Pantotrichum is mended governor vessel, kidney-Yang invigorating, the spermatogenesis marrow, bone and muscle strengthening can warming YANG and replenishing vital essence and blood; The Hippocampus kidney invigorating and YANG supporting has the merit of regulating qi and activating blood again, and the three share principal drug assistance QI invigorating warming YANG, beneficial intensive culture blood, tonify without causing stagnation.Rhizoma Chuanxiong, Rhizoma Corydalis promoting blood circulation to remove obstruction in the collateral, blood-activating analgetic, Rhizoma Chuanxiong are again the gas medicine in the blood, and the hot temperature of loosing is logical, blood-activating and qi-promoting; Olibanum, Myrrha share, and the promoting blood circulation and detumescence pain relieving can granulation promoting be put on flesh again, more than is adjuvant drug, with the active merit of reinforcement monarch-minister drug promoting blood circulation and breaking stagnation latus rectum, and the energy promoting flow of QI and blood, reducing swelling and alleviating pain; The succinum blood circulation promoting and blood stasis dispelling, tranquillizing the mind by relieving convulsion, and the effect of relieving stranguria by diuresis is arranged, to strengthen we's dissipating blood stasis for subsidence of swelling function; Radix Glycyrrhizae has heat-clearing and toxic substances removing, and coordinating the actions of various ingredients in a prescription is so be messenger drug.The all medicines in full side are many through processed with wine, more strengthen the logical merit of full side's temperature.Adopt the said medicine prescription through concoct, technologies such as water is carried, dry, pulverizing, make oral formulations, make said preparation have blood circulation and removing stasis, the QI invigorating warming YANG, the merit of coronary circulation-promoting pain-relieving has benefit in living, and deposits the logical effect of temperature among the tonification again, through Nanchang County, Jiangxi Province vasculitis hospital clinical test, the cure rate of necrosis disease is reached more than 80%.
Below enforcement of the present invention is described in further detail:
The present invention is formed (percentage by weight) with following prescription and consumption:
Amount ranges (%) optimum amount (%)
Fruit of Chinese Azalea 20-25 20
Hirudo 7.5-12.5 10
Radix Notoginseng 7.5-12.5 10
Rhizoma Chuanxiong 7.5-12.5 10
Olibanum 2.5-5 5
Myrrha 2.5-5 5
Rhizoma Corydalis 7.5-12.5 10
Hippocampus 5-7.5 5
Cornu Cervi Pantotrichum 5-7.5 5
Radix Ginseng 5-7.5 5
Succinum 7.5-12.5 10
Borneolum Syntheticum 0.75-12.5 1
Radix Glycyrrhizae 2.5-5 4
Preparation method of the present invention is: at first fruit of Chinese Azalea is concocted separately, Hirudo, Radix Notoginseng, succinum, Olibanum, Myrrha, Hippocampus, Cornu Cervi Pantotrichum, Borneolum Syntheticum powder are broken into the crude drug fine powder; Radix Ginseng, Rhizoma Corydalis, Radix Glycyrrhizae decocting in water extract, and Rhizoma Chuanxiong extracts volatile oil earlier, and medicinal residues and entry are carried.Water is carried the back medicinal liquid and is concentrated into thick paste, is ground into fine powder after the oven dry, crosses 80 mesh sieves, mixes with the crude drug powder again, and spray Rhizoma Chuanxiong volatile oil stirring and evenly mixing is made oral formulations such as capsule, tablet, granule or powder preparation to be taken after being infused in boiling water.
The present invention has blood circulation promoting and blood stasis dispelling, and the effect of coronary circulation-promoting pain-relieving to the obstructed caused thoracic obstruction of blood vessels, apoplexy, particularly has significant curative effect to necrosis disease.
Embodiment 1:
Fruit of Chinese Azalea 20% Hirudo 10% Radix Notoginseng 10% Rhizoma Chuanxiong 10%
Olibanum 5% Myrrha 5% Rhizoma Corydalis 10% Hippocampus 5%
Cornu Cervi Pantotrichum 5% Radix Ginseng 5% succinum 10% Borneolum Syntheticum 1%
Radix Glycyrrhizae 4%
Fruit of Chinese Azalea is concocted; Hirudo, Radix Notoginseng, succinum, Olibanum, Myrrha, Hippocampus, Cornu Cervi Pantotrichum, Borneolum Syntheticum powder are broken into the crude drug fine powder; Radix Ginseng, Rhizoma Corydalis, Radix Glycyrrhizae decocting in water extract; Rhizoma Chuanxiong extracts volatile oil earlier, and medicinal residues and entry are carried.Water is carried the back medicinal liquid and is concentrated into thick paste, is ground into fine powder after the oven dry, crosses 80 mesh sieves, mix with the crude drug powder again, and the spray Rhizoma Chuanxiong volatile oil, mixing is made oral formulations.
Embodiment 2:
Fruit of Chinese Azalea 20% Hirudo 10% Radix Notoginseng 9% Rhizoma Chuanxiong 12.5%
Olibanum 4% Myrrha 4% Rhizoma Corydalis 10% Hippocampus 5% Cornu Cervi Pantotrichum 5% Radix Ginseng 5.5% succinum 10% Borneolum Syntheticum 1% Radix Glycyrrhizae 4% production technology is with embodiment 1.Embodiment 3: fruit of Chinese Azalea 25% Hirudo 7.5% Radix Notoginseng 10% Rhizoma Chuanxiong 10% Olibanum 5% Myrrha 5% Rhizoma Corydalis 7.5% Hippocampus 5% Cornu Cervi Pantotrichum 5% Radix Ginseng 5% succinum 10% Borneolum Syntheticum 1% Radix Glycyrrhizae 4% production technology is with embodiment 1.Embodiment 4: fruit of Chinese Azalea 20% Hirudo 10% Radix Notoginseng 10% Rhizoma Chuanxiong 12% Olibanum 3% Myrrha 3% Rhizoma Corydalis 10% Hippocampus 5% Cornu Cervi Pantotrichum 5% Radix Ginseng 6% succinum 10% Borneolum Syntheticum 1% Radix Glycyrrhizae 5% production technology is with embodiment 1.Embodiment 5: fruit of Chinese Azalea 20% Hirudo 10% Radix Notoginseng 10% Rhizoma Chuanxiong 10% Olibanum 5% Myrrha 5% Rhizoma Corydalis 10% Hippocampus 6% Cornu Cervi Pantotrichum 6% Radix Ginseng 5% succinum 7.5% Borneolum Syntheticum 1.25% Radix Glycyrrhizae 4.25% production technology is with embodiment 1.
Claims (3)
1, a kind of beniol spirit Chinese medicine preparation, form by fruit of Chinese Azalea, Hirudo, Radix Notoginseng, Rhizoma Chuanxiong, Olibanum, Myrrha, Rhizoma Corydalis, Hippocampus, Cornu Cervi Pantotrichum, Radix Ginseng, succinum, Borneolum Syntheticum, Radix Glycyrrhizae, it is characterized in that the proportioning (percentage by weight) of above-mentioned prescription is: fruit of Chinese Azalea 20-25, Hirudo 7.5-12.5, Radix Notoginseng 7.5-12.5, Rhizoma Chuanxiong 7.5-12.5, Olibanum 2.5-5, Myrrha 2.5-5, Rhizoma Corydalis 7.5-12.5, Hippocampus 5-7.5, Cornu Cervi Pantotrichum 5-7.5, Radix Ginseng 5-7.5, succinum 7.5-12.5, Borneolum Syntheticum 0.75-1.25, Radix Glycyrrhizae 2.5-5.
2, beniol spirit Chinese medicine preparation according to claim 1 is characterized in that the optimum formula of said preparation is (percentage by weight): fruit of Chinese Azalea 20, Hirudo 10, Radix Notoginseng 10, Rhizoma Chuanxiong 10, Olibanum 5, Myrrha 5, Rhizoma Corydalis 10, Hippocampus 5, Cornu Cervi Pantotrichum 5, Radix Ginseng 5, succinum 10, Borneolum Syntheticum 1, Radix Glycyrrhizae 4.
3, a kind of production technology of beniol spirit Chinese medicine preparation is characterized in that fruit of Chinese Azalea is concocted separately, and Hirudo, Radix Notoginseng, succinum, Olibanum, Myrrha, Hippocampus, Cornu Cervi Pantotrichum, Borneolum Syntheticum powder are broken into the crude drug fine powder, Radix Ginseng, Rhizoma Corydalis, Radix Glycyrrhizae decocting in water extract, Rhizoma Chuanxiong extracts volatile oil earlier, and medicinal residues and entry are carried, and water is carried the back medicinal liquid and is concentrated into thick paste, be ground into segmentation after the oven dry, cross 80 mesh sieves, mix with the crude drug powder again, spray Rhizoma Chuanxiong volatile oil, stir, make oral formulations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 95107235 CN1140066A (en) | 1995-07-07 | 1995-07-07 | Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 95107235 CN1140066A (en) | 1995-07-07 | 1995-07-07 | Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1140066A true CN1140066A (en) | 1997-01-15 |
Family
ID=5076227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 95107235 Pending CN1140066A (en) | 1995-07-07 | 1995-07-07 | Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1140066A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100409891C (en) * | 2006-01-25 | 2008-08-13 | 张冬 | Pure Chinese medicinal preparation for activating blood circulation, removing blood stasis and relieving pain |
CN101416991B (en) * | 2008-11-29 | 2011-01-26 | 吴红彦 | Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof |
CN103272035A (en) * | 2013-06-03 | 2013-09-04 | 刘建飞 | Sphacelus treatment medicine |
-
1995
- 1995-07-07 CN CN 95107235 patent/CN1140066A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100409891C (en) * | 2006-01-25 | 2008-08-13 | 张冬 | Pure Chinese medicinal preparation for activating blood circulation, removing blood stasis and relieving pain |
CN101416991B (en) * | 2008-11-29 | 2011-01-26 | 吴红彦 | Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof |
CN103272035A (en) * | 2013-06-03 | 2013-09-04 | 刘建飞 | Sphacelus treatment medicine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1148211C (en) | Medicine for treating congestive heart failure | |
CN1286502C (en) | Medicine for treating gout affection and its symptoms | |
CN1344547A (en) | Multieffect stomach-invigorating bolus | |
CN1052901C (en) | A Chinese medicinal pill for treating psoriasis and its preparation method | |
CN1140066A (en) | Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation | |
CN1063088C (en) | Medicine for curing hepatic and gallbladder diseases | |
CN1056301C (en) | 'Lanweiling' oral liquid for treating appendicitis | |
CN102742832B (en) | Dietetic therapy product for protecting joint and preparation method thereof | |
CN101549057A (en) | Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same | |
CN1530122A (en) | Chinese medicine for treating injury | |
CN1195535C (en) | Chinese medicine for rheumatism | |
CN101336990B (en) | Medicine for treating cholecystitis | |
CN100346821C (en) | Medicinal capsule for treating liver and gallbladder diseases and its preparing process | |
CN1051712C (en) | Medicine for rheumatism | |
CN1454648A (en) | Medicinal liquor for curing rheumatism and traumatic injuries | |
CN1105875A (en) | Medicine for treating ascites due to cirrhosis | |
CN1248445A (en) | Medicinal liquor for curing articulation pain and preparation method thereof | |
CN1355047A (en) | Process for preapring compounds clemetis medicine | |
CN1429596A (en) | Manufacturing process of Rujietai preparation | |
CN1070073C (en) | Medicine for treating hypercoagulable blood and its preparing process | |
CN1762440A (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
CN1850259A (en) | Oral Chinese medicine preparation for treating liver and gall bladder diseases | |
CN1836705A (en) | Medicine for treating amblyopia and its preparing method | |
CN1586506A (en) | Jiangbai oral liquid | |
CN1301130C (en) | Hepatic calculus dissolving solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |